Ebola
4
Pipeline Programs
6
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
1100%
+ 5 programs with unclassified modality
Competitive Landscape
6 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Sharp TherapeuticsV920
NovavaxBase Dose EBOV GP Vaccine
Allergy TherapeuticscAd3-EBO Z at 1 x 10^10 vp
Clinical Trials (3)
Total enrollment: 572 patients across 3 trials
African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
Start: Aug 2017Est. completion: Mar 2023251 patients
Phase 2Completed
Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects
Start: Feb 2015Est. completion: Apr 2016230 patients
Phase 1Completed
A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
Start: Sep 2014Est. completion: Aug 201791 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
6 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.